Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients - Wikidata - wikimedia - TriplyDB

Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients

Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients

http://www.wikidata.org/entity/Q35196367

about

Yin Yang gene expression ratio signature for lung cancer prognosis Lung Cancer Gene Signatures and Clinical Perspectives One-step extrapolation of the prediction performance of a gene signature derived from a small study Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer Prognostic value of microRNA expression in operable non-small cell lung cancer patients Predicting Anticancer Drug Responses Using a Dual-Layer Integrated Cell Line-Drug Network Model Incorporating network structure in integrative analysis of cancer prognosis data.An epigenetically distinct breast cancer cell subpopulation promotes collective invasion Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma High-dimensional genomic data bias correction and data integration using MANCIE Sparse group penalized integrative analysis of multiple cancer prognosis datasets.The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.Integrative analysis of high-throughput cancer studies with contrasted penalization.A penalized robust method for identifying gene-environment interactions.Identifying gene-environment and gene-gene interactions using a progressive penalization approach Prediction of Clinical Outcome for All Stages and Multiple Cell Types of Non-small Cell Lung Cancer in Five Countries Using Lung Cancer Prognostic Index.Testing an aflatoxin B1 gene signature in rat archival tissues.A penalized robust semiparametric approach for gene-environment interactions A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.Isolation of microarray-quality RNA from primary human cells after intracellular immunostaining and fluorescence-activated cell sorting.Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases Survival impact index and ultrahigh-dimensional model-free screening with survival outcomes.Profiling cancer testis antigens in non-small-cell lung cancer.Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients.Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer.Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations.microRNAs in colon cancer: a roadmap for discovery.Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis.Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.Adaptive prediction model in prospective molecular signature-based clinical studies.Low-dimensional confounder adjustment and high-dimensional penalized estimation for survival analysis.Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer.MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.Individual-level analysis of differential expression of genes and pathways for personalized medicine.Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer.

P2860

Q28385778-B29D8083-D152-4CC4-ADC1-131E3E05B216 Q28387769-32491092-B6A6-4896-BFB0-148D744A711B Q28392088-071BF3AE-1D22-4C55-8CF8-9F3F8092F02E Q28393146-41781BC9-8428-4324-9466-E648285902D1 Q28394974-19C87BEA-4BC2-46D8-9909-5630B2CFBBF3 Q28396343-99003F74-F093-487B-A250-0538BFA0919A Q28548616-61844065-9E61-424C-99BD-D51B60BBD4C9 Q30577859-2B4F263F-36EE-478A-B40B-E60C1B590F45 Q30654061-A349246F-61A6-4400-AD9B-9906D7492A84 Q30830295-1E787A95-B43D-4B8A-B46C-4CEADEC6FBB5 Q31075558-2DF79423-8BD6-46E8-BC0C-E4E56D266C36 Q33876092-19D27421-3C31-420C-9DC5-363E6BAA3028 Q34373936-2EA27C8D-E04A-4232-8BB6-B874C83D0685 Q35164722-44DBD345-D211-46CF-AD82-236C482EF1E6 Q35167212-47FE1DA9-06F1-4D05-A42B-E34D1C270041 Q35167216-A51ED7BB-3FDC-4996-98EA-1BCD9F0B438A Q35687989-5669D363-DF98-47F2-8DAA-27C304AED47B Q35981453-3713E029-DF06-465E-BE39-9DAABFCEF074 Q36469955-B84D5DAD-28B9-4626-9B66-645B1CB15B18 Q36746536-6C480EDF-0EA0-4A21-A260-A1FA06428154 Q36770254-3014D211-66DD-4A19-BAF6-4646C3A7F97B Q37069498-BB22EC2E-D926-4AFE-A8F6-DC70ED3D30B8 Q37163109-5FCFC7E0-1373-412E-AC29-D7F3DD504229 Q37194807-3AE0D9BC-9A4E-4755-B432-B31C0122BF07 Q37277266-4C20610A-61C3-424D-8525-BDA96D00D30E Q37564046-4991795F-3AF2-4824-AE1F-E450BED41628 Q37696112-61317D2C-35DE-4139-B391-294A082A0A2B Q37699284-784B78A8-1BEA-4DD7-8118-DFDBC67DA53D Q38010665-35C7C69F-35E1-4814-866E-D6A8593D8EED Q38061129-F837D2EF-E4FF-449F-8496-8EE3C714CA6E Q38107464-D4037173-253A-4BA9-9893-4838B3F58DFA Q38688789-A4491A26-295E-4C2C-96A1-96E39043C35C Q38915283-6D49953E-46CC-4BC5-9FA7-8C24CF42BFB4 Q39180729-25EAD59F-A5B4-4578-ABCE-2E1DD0C2A77E Q39297978-144AADD1-26D4-4A9B-A98F-5FF421C64FEF Q40435695-4BD54A3E-63DA-42BA-A262-8447822ED76C Q40646057-A709C03E-9866-4184-B96A-998E49ACAFE9 Q41008660-6F500E1E-B3F2-40ED-A7AB-C27122A9BB3F Q42200053-CCD21524-A8D8-4E8D-9AD0-81ED021CB6D8 Q43889503-7B68262B-134B-4CCB-B6F6-4F98FE64B7CB

P2860

Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients

http://www.wikidata.org/entity/Q35196367

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Robust gene expression signatu ...... mall-cell lung cancer patients

@ast

Robust gene expression signatu ...... mall-cell lung cancer patients

@en

type

label

Robust gene expression signatu ...... mall-cell lung cancer patients

@ast

Robust gene expression signatu ...... mall-cell lung cancer patients

@en

prefLabel

Robust gene expression signatu ...... mall-cell lung cancer patients

@ast

Robust gene expression signatu ...... mall-cell lung cancer patients

@en

P1433

Q35196367-66CED1F6-27C4-4F70-A7ED-BEFD53BB7671

P1476

Q35196367-FFE8B5F3-8D8E-4388-ACD0-BAAFCBD9C7F4

P2093

Q35196367-2344DE66-B7AA-478B-8A82-9C1C27FB4271

Q35196367-44BEE187-309F-47D7-8F93-918E54AA8671

Q35196367-5237EAC9-F41D-4B86-97EA-F64551D6214C

Q35196367-53A13B57-8275-44BB-9D90-C3985C8738E4

Q35196367-6A25E06F-DF82-4235-9E30-0C4583C0A543

Q35196367-C8441518-53F5-4F4C-B2A7-D9467E8D37D5

Q35196367-D524520D-E888-4464-82AD-6B0074A394B0

Q35196367-E320436B-1804-49D3-AF22-4FCD0651610C

Q35196367-E366F2CE-4B39-4DA6-B4BB-1C1E037FADE1

Q35196367-E59A7093-1F42-48C8-8FB1-774BC8776E35

P2860

Q35196367-01F2A7AE-59AD-4312-82E5-2777F84E6763

Q35196367-0F1CEB51-36E6-48E1-94B5-3C8BCB7162AD

Q35196367-19FD4DDC-D37E-47D1-9E2C-B0DD247F3C16

Q35196367-21AD93AA-B82E-4207-8807-B1E5F9448D62

Q35196367-24683516-A85A-409A-8EB2-B56AD8C3A5A1

Q35196367-263162FA-576A-4E95-8C2E-1D74BA0A65DE

Q35196367-2FA7D8D5-8260-4659-96C4-574630DA4894

Q35196367-3508C47B-AB14-414E-B19E-89DFC0FFF884

Q35196367-3702AF98-1FC8-4D76-8154-B0ACEF766688

Q35196367-3BF21A58-0034-4763-AFAE-F50FBBF6DAF8

P304

Q35196367-3F963357-1DA0-4C57-95DF-480EFFD79929

P31

Q35196367-707FF33D-E879-424D-821D-9F2D884F5946

P356

Q35196367-C7FA9DF4-7BE7-459D-BE4E-8C32AF87D78E

P407

Q35196367-DF6806AA-0E9C-459A-9396-8A3B190266A1

P433

Q35196367-DC4ADE3A-4AD4-47FE-9EDE-E881E3A5C319

P478

Q35196367-F2032FCB-D9E7-42AF-9C06-C9052C71878D

P50

Q35196367-ED2E032C-2B8E-481A-9316-1F063CDE1BDC

Q35196367-F10AEA3C-F82C-4341-80C1-B4E0EF5ED8C5

Q35196367-FCA3BB04-1237-4548-88F0-0487BDDE2408

P577

Q35196367-2C798AFB-BB78-4673-BF8E-6C6C5833D32F

P698

Q35196367-6E4B8342-2BA8-4D36-AE07-79609754C1C1

P932

Q35196367-160F1D87-7E63-415F-9F6D-43C6175C621F

P356

1078-0432.CCR-11-0196

P1433

Clinical Cancer Research

P1476

Robust gene expression signatu ...... mall-cell lung cancer patients

@en

P2093

Carmen Behrens

http://www.w3.org/2001/XMLSchema#string

Cesar Moran

http://www.w3.org/2001/XMLSchema#string

Gabriela Raso

http://www.w3.org/2001/XMLSchema#string

Guanghua Xiao

http://www.w3.org/2001/XMLSchema#string

Heidi S Erickson

http://www.w3.org/2001/XMLSchema#string

Jack Roth

http://www.w3.org/2001/XMLSchema#string

John D Minna

http://www.w3.org/2001/XMLSchema#string

Kathy Danenberg

http://www.w3.org/2001/XMLSchema#string

Luc Girard

http://www.w3.org/2001/XMLSchema#string

Luisa M Solis

http://www.w3.org/2001/XMLSchema#string

P2860

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

Semi-supervised methods to predict patient survival from gene expression data

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

Gene expression profiling predicts clinical outcome of breast cancer

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

Repeatability of published microarray gene expression analyses

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer

Cancer statistics, 2009

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

P304

5705-5714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-0196

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Kevin R. Coombes

Ignacio I Wistuba

P577

2011-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21742808

http://www.w3.org/2001/XMLSchema#string

P932

3166982

http://www.w3.org/2001/XMLSchema#string